NCT03785249 2025-09-30Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1Mirati Therapeutics Inc.Phase 1/2 Active not recruiting731 enrolled 2 FDA
NCT05634525 2025-07-25Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer PatientsM.D. Anderson Cancer CenterPhase 1 Withdrawn